Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,701–1,800 of 4,275
Aging human abdominal subcutaneous white adipose tissue at single cell resolution
Whytock, K. L., Divoux, A., Sun, Y., Pino, M. F., Yu, G., Jin, C. A., Robino, J. J., Plekhanov, A., Varlamov, O., Smith, S. R., et al. (2024) · Aging Cell · doi:10.1111/acel.14287 · Cited by 41
“…to cells that are resistant to regulated cell death (Wang, 1995 ) and secrete chemokines, cytokines, growth factors, and matrix metalloproteinases (Coppé et al., 2008) in proliferating cell types but has also been found in terminally differentiated cells (Farr et al., 2016 ; Jurk et al., 2012)…”
Self-citationThe Biology of Aging and Lymphoma: a Complex Interplay
Sarkozy, C., Salles, G. A., & Falandry, C. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0457-x · Cited by 37
Premature expression of a muscle fibrosis axis in chronic HIV infection
Kusko, R. L., Banerjee, C., Long, K. K., Darcy, A., Otis, J. S., Sebastiani, P., Melov, S., Tarnopolsky, M. A., Bhasin, S., & Montano, M. A. (2012) · Skeletal Muscle · doi:10.1186/2044-5040-2-10 · Cited by 34
“Recent studies on senescence and aging indicate that cellular senescence is accompanied by a striking increase in the secretion of 40 to 80 factors [34,38,65,66], termed the ‘senescence-associated secretory phenotype’ or SASP [35], an ensemble of factors that includes multiple inflammatory cytokines.”
BackgroundInfluentialBacterial exopolysaccharides: Characteristics and antioxidant mechanism
Dong, J., Chi, Z., Lu, S., Xie, X., Gong, P., Li, H., & Liu, W. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.138849 · Cited by 39
Transplanting old organs promotes senescence in young recipients
Iske, J., Roesel, M. J., Martin, F., Schroeter, A., Matsunaga, T., Maenosono, R., Tripathi, U., Xiao, Y., Nian, Y., Caldarone, B. J., et al. (2023) · American Journal of Transplantation · doi:10.1016/j.ajt.2023.10.013 · Cited by 37
Connecting cancer relapse with senescence
Pluquet, O., Abbadie, C., & Coqueret, O. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.08.004 · Cited by 39
Aging of the human innate immune system in HIV infection
Zapata, H. J., & Shaw, A. C. (2014) · Current Opinion in Immunology · doi:10.1016/j.coi.2014.06.007 · Cited by 35
“from ionizing radiation or replicative exhaustion) [72,73], though it is worth noting that there is a paucity of data demonstrating an in vivo role for the SASP.”
BackgroundGlutamine promotes escape from therapy-induced senescence in tumor cells
Pacifico, F., Badolati, N., Mellone, S., Stornaiuolo, M., Leonardi, A., & Crescenzi, E. (2021) · Aging · doi:10.18632/aging.203495 · Cited by 37
“Second, senescent tumor cells develop a secretory phenotype or SASP, and secrete cytokines and growth factors [5] that reinforce the senescent growth arrest and activate the anti-tumor immune response [49].”
Giuliani, A., Giudetti, A. M., Vergara, D., Coco, L. D., Ramini, D., Caccese, S., Sbriscia, M., Graciotti, L., Fulgenzi, G., Tiano, L., et al. (2023) · Antioxidants · doi:10.3390/antiox12111956 · Cited by 45
“In fact, senescent endothelial cells acquire a characteristic proinflammatory secretory phenotype, i.e., SASP, which perpetuates the inflammatory state in the vascular environment [3], resulting in chronic low-grade inflammation, referred to as inflammaging [4].”
BackgroundPreininger, M. K., Zaytseva, D., Lin, J. M., & Kaufer, D. (2023) · Aging Cell · doi:10.1111/acel.13747 · Cited by 36
NGAL as a Potential Target in Tumor Microenvironment
Crescenzi, E., Leonardi, A., & Pacifico, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212333 · Cited by 38
“As positive mediators, SASP factors enable proper embryonic development, activate and regulate wound healing and trigger immune clearance of senescent cells [79–81].”
BackgroundInfluentialMesenchymal Stromal Cell Secretome Is Affected by Tissue Source and Donor Age
Turło, A., Hammond, D. E., Ramsbottom, K. A., Soul, J., Gillen, A. M., McDonald, K., Peffers, M. J., & Clegg, P. (2023) · Stem Cells · doi:10.1093/stmcls/sxad060 · Cited by 46
PKCη promotes senescence induced by oxidative stress and chemotherapy
Zurgil, U., Ben-Ari, A., Atias, K., Isakov, N., Apte, R. N., & Livneh, E. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.481 · Cited by 35
“Among these, IL-6 secretion was implicated in reinforcing senescence(5,40) but also in promoting tumor invasiveness.(41) We have initially determined the transcription of cytokines in PKCη-knockdown cells using RT-PCR in response to oxidative”
Tubita, A., Lombardi, Z., Tusa, I., Lazzeretti, A., Sgrignani, G., Papini, D., Menconi, A., Gagliardi, S., Lulli, M., Sbarba, P. D., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0993 · Cited by 51
“Among the latter, transcriptomic analysis indicated that CXCL1/GROalpha and CXCL8/IL8, two of the most prominent SASP products (33), and CCL20/MIP3alpha mRNA were signi fi cantly upregulated in both A375 and SK-Mel-5 ERK5-KD cells ( Fig.”
Malavolta, M., Costarelli, L., Giacconi, R., Piacenza, F., Basso, A., Pierpaoli, E., Marchegiani, F., Cardelli, M., Provinciali, M., & Mocchegiani, E. (2014) · Nutrition Research · doi:10.1016/j.nutres.2014.02.006 · Cited by 37
“[26] Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al.”
BackgroundIRE1α drives lung epithelial progenitor dysfunction to establish a niche for pulmonary fibrosis
Auyeung, V. C., Downey, M. S., Kathiriya, J. J., Thamsen, M., Wenger, T. A., Backes, B. J., Brumwell, A. N., Chapman, H. A., Sheppard, D., & Papa, F. R. (2022) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00408.2021 · Cited by 37
Nagarajan, P., Chin, S. S., Wang, D., Liu, S., Sinha, S., & Garrett‐Sinha, L. A. (2010) · Journal of Cell Science · doi:10.1242/jcs.062240 · Cited by 41
“Key words: Mmp, Chemokine, Differentiation, Keratinocyte, Transgenic, EGF ligand Jo ur na l o f C el l S ci en ce proliferation and migration (Cataisson et al., 2009; Coppe et al., 2008; Coussens et al., 1999; Takahashi et al., 2010).”
Aifuwa, I., Giri, A., Longe, N., Lee, S., An, S. S., & Wirtz, D. (2015) · Oncotarget · doi:10.18632/oncotarget.5854 · Cited by 40
“We note that both WI-38 and T47D are standard cell lines used extensively to study the interplay between senescence of fibroblasts and cancer [5, 7, 13].”
BackgroundInfluentialFernández-Duran, I., Quintanilla, A., Tarrats, N., Birch, J., Hari, P., Millar, F. R., Lagnado, A. B., Smer-Barreto, V., Muir, M., Brunton, V. G., et al. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00917-6 · Cited by 39
Rare progerin-expressing preadipocytes and adipocytes contribute to tissue depletion over time
Revêchon, G., Viceconte, N., McKenna, T., Sola-Carvajal, A., Vrtačnik, P., Stenvinkel, P., Lundgren, T., Hultenby, K. R., Franco, I., & Eriksson, M. (2017) · Scientific Reports · doi:10.1038/s41598-017-04492-0 · Cited by 38
Wang, C., Long, Q., Fu, Q., Xu, Q., Fu, D., Li, Y., Gao, L., Guo, J., Zhang, X., Lam, E. W. ‐., et al. (2021) · Oncogene · doi:10.1038/s41388-022-02476-7 · Cited by 39
“Of note, senescent cells secrete a plethora of cytokines, chemokines, growth factors and proteases that profoundly affect neighboring cells, a phenomenon termed the senescence-associated secretory phenotype (SASP) [6].”
BackgroundSelf-citationTo target cellular senescence in diabetic kidney disease: the known and the unknown
Wei, Y., Mou, S., Yang, Q., Liu, F., Cooper, M. E., & Chai, Z. (2024) · Clinical Science · doi:10.1042/cs20240717 · Cited by 44
The central role of DNA damage in immunosenescence
Kell, L., Simon, A. K., Alsaleh, G., & Cox, L. S. (2023) · Frontiers in Aging · doi:10.3389/fragi.2023.1202152 · Cited by 47
“Additionally, immunosenescence is associated with a low-grade inflammatory environment that is generated, at least in part, by the SASP of senescent cells of both immune and non-immune origin (Teissier et al., 2022).”
BackgroundInfluentialIL-23R is a senescence-linked circulating and tissue biomarker of aging
Carver, C. M., Rodriguez, S. L., Atkinson, E. J., Dosch, A. J., Asmussen, N. C., Gomez, P. T., Leitschuh, E. A., Espíndola‐Netto, J. M., Jeganathan, K. B., Whaley, M. G., et al. (2024) · Nature Aging · doi:10.1038/s43587-024-00752-7 · Cited by 43
“Many of the proteins that were higher in aged plasma were secreted factors 16,39 .”
Disruptive chemicals, senescence and immortality
Carnero, A., Blanco-Aparicio, C., Kondoh, H., Lleonart, M. E., Martinez-Leal, J. F., Mondello, C., Scovassi, A. I., Bisson, W. H., Amedei, A., Roy, R., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv029 · Cited by 29
Oei, S., Millar, C. L., Lily, T. N. N., Mukamal, K. J., Kiel, D. P., Lipsitz, L. A., Hannan, M. T., & Sahni, S. (2023) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2023.04.013 · Cited by 35
Past and Future Directions for Research on Cellular Senescence
Zhu, Y. Z., Anastasiadis, Z. P., Espíndola‐Netto, J. M., Evans, T. S., Tchkonia, T., & Kirkland, J. L. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041205 · Cited by 39
The Connection Between Cell Fate and Telomere
Engin, A. B., & Engin, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-49844-3_3 · Cited by 41
Autophagy-mediated control of ribosome homeostasis in oncogene-induced senescence
López, A. R., Jørgensen, M. H., Havelund, J. F., Arendrup, F. S., Kolapalli, S. P., Nielsen, T. M., Pais, E., Beese, C. J., Abdul-Al, A., Vind, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113381 · Cited by 40
Haarer, E. L., Theodore, C. J., Guo, S., Frier, R. B., & Campellone, K. G. (2023) · PLoS Genetics · doi:10.1371/journal.pgen.1010045 · Cited by 39
Targeting senescent cells to reshape the tumor microenvironment and improve anticancer efficacy
Jiang, B., Zhang, W., Zhang, X., & Sun, Y. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.05.002 · Cited by 39
Self-citationRole of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers
Netti, G. S., Franzin, R., Stasi, A., Spadaccino, F., Strologo, A. D., Infante, B., Gesualdo, L., Castellano, G., Ranieri, E., & Stallone, G. (2021) · Cells · doi:10.3390/cells10092426 · Cited by 37
“Prostate cancer patients treated with the chemotherapeutic mitoxantrone showed an increased expression of various senescenceassociated genes (p16, p21) and numerous SASP markers, including IL-6 and IL-8 [36].”
BackgroundRohn, F., Kordes, C., Buschmann, T., Reichert, D., Wammers, M., Poschmann, G., Stühler, K., Benk, A. S., Geiger, F., Spatz, J. P., et al. (2020) · Aging Cell · doi:10.1111/acel.13131 · Cited by 34
“In addition to protein arrays, ELISA analyses of CXCL3 and IL6 were performed to investigate additional SASP factors at the protein level.”
BackgroundInfluentialSphingolipids at the Crossroads of NAFLD and Senescence
Nikolova‐Karakashian, M. (2018) · Advances in cancer research · doi:10.1016/bs.acr.2018.05.002 · Cited by 39
Early growth response 2 (EGR2) is a novel regulator of the senescence programme
Tyler, E. J., del Arroyo, A. G., Wallis, R., Hughes, B., Garbe, J. C., Stampfer, M. R., Koh, J., Lowe, R., Philpott, M. P., & Bishop, C. L. (2021) · Aging Cell · doi:10.1111/acel.13318 · Cited by 38
“Further characterisation of the changes to the senescence phenotype following ablation of the EGR2 in DS HMFs revealed a significant down- regulation of the SASP factor, IL- 6, at the transcript level (Figure 3e) and at the secreted protein level (Figure 3f).”
BackgroundInfluentialImpaired BCAA catabolism in adipose tissues promotes age-associated metabolic derangement
Han, H.-S., Ahn, E., Park, E. S., Huh, T., Choi, S., Kwon, Y., Choi, B. H., Lee, J., Choi, Y. H., Jeong, Y. L., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00460-8 · Cited by 41
Senescence from glioma stem cell differentiation promotes tumor growth
Ouchi, R., Okabe, S., Migita, T., Nakano, I., & Seimiya, H. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.01.071 · Cited by 37
Context‐dependent roles of cellular senescence in normal, aged, and disease states
Moiseeva, V., Cisneros, A., Cobos, A. C., Tarrega, A. B., Oñate, C. S., Perdiguero, E., Serrano, A. L., & Muñoz‐Cánoves, P. (2023) · The FEBS Journal · doi:10.1111/febs.16573 · Cited by 34
CD20-Targeting Immunotherapy Promotes Cellular Senescence in B-Cell Lymphoma
Däbritz, J. H. M., Yu, Y., Milanovic, M., Schönlein, M., Rosenfeldt, M. T., Dörr, J. R., Kaufmann, A. M., Dörken, B., & Schmitt, C. A. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0627 · Cited by 37
“Consistent with the dose-dependent fractions of senescent cells generated in response to ADR, we also found IL6 and IL8, two major components of the SASP (23, 25), atmuchhigher concentrations in the culture supernatant of RC-K8 cells exposed to 10 ng/mL instead of 5 ng/mL of ADR (Fig.”
BackgroundBiological Aspects of Inflamm-Aging in Childhood Cancer Survivors
Rossi, F., Paola, A. D., Pota, E., Argenziano, M., Pinto, D., Marrapodi, M. M., Leva, C. D., Martino, M. D., & Tortora, C. (2021) · Cancers · doi:10.3390/cancers13194933 · Cited by 39
“Inflammation is responsible for the activation of two important cytotoxic mediators, ROS and reactive nitrogen species (RNS), which determine DNA damage [32,33].”
BackgroundDucloux, D., Legendre, M., Bamoulid, J., Saas, P., Courivaud, C., & Crépin, T. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.720402 · Cited by 41
Characterizing microglial senescence: Tau as a key player
Karabag, D., Scheiblich, H., Griep, A., Santarelli, F., Schwartz, S., Heneka, M. T., & Ising, C. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15866 · Cited by 38
“While several SASP factors seem to be common among senescent cells, the final composition of the SASP is highly dependent on the senescence- inducing stressor as well as cell type investigated (Basisty et al., 2020; Coppé et al., 2008).”
BackgroundMycotoxins and cellular senescence: the impact of oxidative stress, hypoxia, and immunosuppression
Li, Y., Nepovimová, E., Valko, M., Wu, Q., & Kuča, K. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03423-x · Cited by 39
Iketani, M., Sekimoto, K., Igarashi, T., Takahashi, M. M., Komatsu, M., Sakane, I., Takahashi, H., Kawaguchi, H., Ohtani‐Kaneko, R., & Ohsawa, I. (2018) · Scientific Reports · doi:10.1038/s41598-018-35239-0 · Cited by 37
Titration of RAS alters senescent state and influences tumour initiation
Chan, A. S. L., Zhu, H., Narita, M., Cassidy, L. D., Young, A. R. J., Bermejo‐Rodríguez, C., Janowska, A. T., Chen, H., Gough, S., Oshimori, N., et al. (2024) · Nature · doi:10.1038/s41586-024-07797-z · Cited by 38
“4b,c), particularly pathways related to the inflammatory response, largely driven by genes encoding well-described SASP factors 31–33 , although not all other classical OIS markers, including Cdkn2a (encoding p16), were upregulated, even in the XL cells (Fig.”
Ikegami, K., Yamashita, M., Suzuki, M., Nakamura, T., Hashimoto, K., Kitagaki, J., Yanagita, M., Kitamura, M., & Murakami, S. (2023) · Aging · doi:10.18632/aging.204569 · Cited by 48
The tumor suppressor ING1 contributes to epigenetic control of cellular senescence
Abad, M., Moreno, A., Palacios, A., Narita, M., Blanco, F. J., Moreno‐Bueno, G., Narita, M., & Palmero, I. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00651.x · Cited by 43
“, 2008), but they can also promote senescence (Acosta et al., 2008; Coppe et al., 2008; Kuilman et al., 2008; Wajapeyee et al., 2008; Rodier et al., 2009) defining the so-called SASP or senescencemessaging secretome (SMS) (Kuilman & Peeper, 2009).”
BackgroundFrom Development to Aging: The Path to Cellular Senescence
Sacco, A., Belloni, L., & Latella, L. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2020.8071 · Cited by 41
“The SASP comprises interleukins (ILs), chemokines, growth factors, secreted proteases, and extracellular matrix components (31).”
BackgroundDiniz, B. S., Vieira, E. M., Mendes‐Silva, A. P., Bowie, C. R., Butters, M. A., Fischer, C. E., Flint, A., Herrmann, N., Kennedy, J., Lanctôt, K. L., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12129 · Cited by 33
Mellado-López, M., Griffeth, R. J., Meseguer-Ripolles, J., Cugat, R., García-Balletbó, M., & Moreno‐Manzano, V. (2017) · Stem Cells International · doi:10.1155/2017/5946527 · Cited by 35
“There is increasing evidence that cellular senescence is a cause of stem cell aging and malignancy [39].”
BackgroundABCC6 knockdown in HepG2 cells induces a senescent-like cell phenotype
Miglionico, R., Ostuni, A., Armentano, M. F., Milella, L., Crescenzi, E., Carmosino, M., & Bisaccia, F. (2017) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-017-0036-2 · Cited by 33
“As a consequence, ABCC6 knockdown HepG2 cells, which show a characteristic gene expression profile, could also adopt an altered secretory phenotype that may modify the tissue microenvironment, as already shown for several types of senescent cells [36, 37] including senescent hepatocytes [38].”
Histone demethylase JMJD3 at the intersection of cellular senescence and cancer
Perrigue, P. M., Najbauer, J., & Barciszewski, J. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.002 · Cited by 36
“Other studies support the fact that the SASP is detrimental to normal tissues and is independent from p16 and p53 pathways [9, 70-72].”
Medeiros Tavares Marques, J. C., Cornélio, D. A., Nogueira Silbiger, V., Ducati Luchessi, A., de Souza, S., & Batistuzzo de Medeiros, S. R. (2017) · Scientific Reports · doi:10.1038/s41598-017-16224-5 · Cited by 33
Cho, S., Kim, A. Y., Kim, J., Choi, D. H., Son, E., & Shin, D. W. (2019) · British Journal of Dermatology · doi:10.1111/bjd.17824 · Cited by 37
Miller, S., Campbell, C. E., Jimenez-Corea, H. A., Wu, G., & Logan, R. A. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.824191 · Cited by 37
Crosstalk between P53 and DNA damage response in ageing
Mohammadzadeh, A., Mirza‐Aghazadeh‐Attari, M., Hallaj, S., Saei, A. A., Alivand, M. R., Valizadeh, A., Yousefi, B., & Majidinia, M. (2019) · DNA repair · doi:10.1016/j.dnarep.2019.05.004 · Cited by 36
Teissier, T., Temkin, V., Pollak, R. D., & Cox, L. S. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.812157 · Cited by 39
“Most notably, while senescent cells are metabolically active, they show marked changes in gene expression and adopt a secretory phenotype, producing a large range of cytokines, chemokines, growth factors and tissue remodeling factors, collectively known as the senescence-associated secretory phenotype, or SASP (Coppe…”
BackgroundSenescence-Inflammatory Regulation of Reparative Cellular Reprogramming in Aging and Cancer
Menéndez, J. A., & Alarcón, T. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00049 · Cited by 34
“…as MMP3, growth factors such as HGF and TGFβ, inflammatory chemokines such as CCL2 and CLL11, and prominent proinflammatory cytokines such as IL1α/β, IL-6, and IL-8 (Coppé et al., 2008; Kuilman and Peeper, 2009; Orjalo et al., 2009; Rodier et al., 2009; Gross et al., 2012; Acosta et al., 2013).”
BackgroundMamun, A. A., Sufian, M. A., Uddin, M. S., Sumsuzzman, D. M., Jeandet, P., Islam, M. S., Zhang, H., Kong, A. T., & Sarwar, M. S. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174991 · Cited by 40
Yue, S., Zheng, X., & Zheng, Y. (2019) · Aging Cell · doi:10.1111/acel.12952 · Cited by 34
“…to initiate and maintain cellular senescence (Acosta et al., 2008; Kuilman et al., 2008) and since the senescence of human and mouse fibroblasts is accompanied by lamin‐B1 reduction (Coppe et al., 2008; Dreesen et al., 2013), we examined whether TNF‐α, IL‐1β, and IL‐6 triggered TEC senescence.”
BackgroundPramotton, F. M., Spitz, S., & Kamm, R. D. (2024) · Advanced Science · doi:10.1002/advs.202403892 · Cited by 39
Petit, M., Kozieł, R., Etemad, S., Pircher, H., & Jansen‐Dürr, P. (2017) · Experimental Gerontology · doi:10.1016/j.exger.2017.03.004 · Cited by 35
“Many senescent cells also secrete several cytokines, growth factors, and matrix metalloproteinases, collectively referred to as the senescence-associated secretory phenotype (SASP; (Coppe et al., 2008; Malaquin et al., 2016).”
BackgroundUp‐regulation of the interferon‐related genes in BRCA2 knockout epithelial cells
Xu, H., Xian, J., Viré, E. A., McKinney, S. E., Wei, V., Wong, J. W. H., Tong, R., Kouzarides, T., Caldas, C., & Aparicio, S. A. J. R. (2014) · The Journal of Pathology · doi:10.1002/path.4404 · Cited by 34
“Some reports attribute the expression of IFN-related genes to cellular senescence [38,39].”
BackgroundLung microbiome in human immunodeficiency virus infection
Twigg, H. L., Weinstock, G. M., & Knox, K. S. (2016) · Translational research · doi:10.1016/j.trsl.2016.07.008 · Cited by 39
“Paradoxically, senescent lymphocytes secrete an inflammatory cytokine profile.(49,50) As a result, tissues containing abundant senescent immune cells are characterized by chronic inflammation.”
GROα regulates human embryonic stem cell self-renewal or adoption of a neuronal fate
Krtolica, A., Larocque, N., Genbacev, O., Ilic, D., Coppe, J.-P., Patil, C. K., Zdravkovic, T., McMaster, M., Campisi, J., & Fisher, S. J. (2011) · Differentiation · doi:10.1016/j.diff.2011.01.001 · Cited by 33
“In these experiments, the signal produced by the bound antibody was amplified by using 35S-labeled streptavidin for detection, a modification that we previously introduced, which improves the reproducibility and sensitivity of this approach (Coppe et al. 2008).”
MethodInfluentialSelf-citationShriki, A., Lanton, T., Sonnenblick, A., Levkovitch-Siany, O., Eidelshtein, D., Abramovitch, R., Rosenberg, N., Pappo, O., Elgavish, S., Nevo, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0321 · Cited by 34
“Moreover, consistent with the role of the SASP in reinforcing senescence-imposed cell-cycle arrest (44), levels of compensatory hepatocyte proliferation (Ki-67) increased by about 50% in young IL6 signaling–deficient strains relative to Mdr2 / controls (P < 0.05; Fig.”
BackgroundInfluentialZhou, L., Zhang, X. K., Dong, Y., Pan, Y. J., Li, J. X., Zang, Y., & Li, X. (2022) · ACS Sensors · doi:10.1021/acssensors.2c00719 · Cited by 33
Metabolaging: a new geroscience perspective linking aging pathologies and metabolic dysfunction
Khalaf, F., Barayan, D., Saldanha, S., & Jeschke, M. G. (2025) · Metabolism · doi:10.1016/j.metabol.2025.156158 · Cited by 45
Aberrant induction of p19Arf-mediated cellular senescence contributes to neurodevelopmental defects
Rhinn, M., Zapata-Bodalo, I., Klein, A., Plassat, J., Knauer-Meyer, T., & Keyes, W. M. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001664 · Cited by 35
“However, the SASP can also exert other effects including 82 promoting cell proliferation, angiogenesis, epithelial-mesenchymal transition (EMT), in addition 83 to cell plasticity and stemness (Coppé et al., 2008; Mosteiro et al., 2016; Ritschka et al., 2017).”
Decellularized Cell‐Secreted Extracellular Matrices as Biomaterials for Tissue Engineering
Ramos‐Rodriguez, D. H., & Leach, J. K. (2024) · Small Science · doi:10.1002/smsc.202400335 · Cited by 38
Ohnishi, T., Yamada, K., Iwasaki, K., Tsujimoto, T., Higashi, H., Kimura, T., Iwasaki, N., & Sudo, H. (2019) · Scientific Reports · doi:10.1038/s41598-019-55709-3 · Cited by 36
A Mitochondrial view of aging, reactive oxygen species and metastatic cancer
Ladiges, W., Wanagat, J., Preston, B. D., Loeb, L. A., & Rabinovitch, P. S. (2010) · Aging Cell · doi:10.1111/j.1474-9726.2010.00579.x · Cited by 34
“Campisi’s group has evidence to suggest that soluble factors released by the hypersecretory senescent cells that accumulate in the stroma of aging tissues can facilitate tumor progression via the diffusion of mitogens and the alteration of extracellular matrix via the enzymatic actions of collagenases and elastases (C…”
BackgroundInfluentialBile Acids and Deregulated Cholangiocyte Autophagy in Primary Biliary Cholangitis
Sasaki, M., & Nakanuma, Y. (2017) · Digestive Diseases · doi:10.1159/000450913 · Cited by 35
Grün, L. K., Maurmann, R. M., Scholl, J. N., Fogaça, M. E., Schmitz, C. R. R., Dias, C. K., Gasparotto, J., Padoin, A. V., Mottin, C. C., Klamt, F., et al. (2023) · Immunity & Ageing · doi:10.1186/s12979-023-00378-0 · Cited by 38
“Cellular senescence entails a proliferative cell cycle arrest with the acquisition of a pro-inflammatory senes-cence‐associated secretory phenotype (SASP) [19] The presence of senescent cells has been causally associated with the appearance of multiple age-associated diseases [20].”
BackgroundWang, W., Chen, X., & Cai, G. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111403 · Cited by 39
Thermogenic adipose tissue aging: Mechanisms and implications
Silva, G. D. N., & Amato, A. A. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.955612 · Cited by 41
“includes upregulation of genes related to cell cycle arrest and induction of the senescence-associated secretory program consisting of cytokines, chemokines, proteases, and growth factors (Coppé et al., 2008).”
BackgroundSubedi, S., Guntipally, M., Suwal, N., Thapa, R., Bashyal, S., Panth, N., Gupta, G., MacLoughlin, R. J., Oliver, B. G. G., Dua, K., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102813 · Cited by 40
Wolf, J., Weinberger, B., & Grubeck‐Loebenstein, B. (2012) · Immunity & Ageing · doi:10.1186/1742-4933-9-1 · Cited by 35
“Previous work with fibroblasts showed that cellular senescence is associated with changes in gene expression, particularly of the cellular secretome (senescence-associated secretory phenotype; SASP) [10,13,14].”
BackgroundIshiguro, N., & Yoshida, H. (2016) · Neoplasia · doi:10.1016/j.neo.2016.08.001 · Cited by 32
“The statistical significances were determined by Student's t-test and P values b.05 were considered to be statistically significant.”
MethodROCK inhibition modulates the senescence‐associated secretory phenotype (SASP) in oral keratinocytes
Niklander, S. E., Bandaru, D., Lambert, D., & Hunter, K. D. (2020) · FEBS Open Bio · doi:10.1002/2211-5463.13012 · Cited by 33
Senescence and SASP Are Potential Therapeutic Targets for Ischemic Stroke
Ouvrier, B., Ismael, S., & Bix, G. J. (2024) · Pharmaceuticals · doi:10.3390/ph17030312 · Cited by 38
“SASP secretes many different growth factors, cytokines, and proteases into the extra-cellular environment, with a few, such as IL-1 α and IL-6, performing both an autocrine pro-senescent feedback loop and paracrine signaling to adjacent cells [2,33,42].”
BackgroundMultiparameter flow cytometric detection and quantification of senescent cells in vitro
Adewoye, A. B., Tampakis, D., Follenzi, A., & Stolzing, A. (2020) · Biogerontology · doi:10.1007/s10522-020-09893-9 · Cited by 33
Wei, Z., Guo, H., Liu, Z., Zhang, X., Liu, Q., Qian, Y., Gong, Y., & Shao, C. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.010 · Cited by 30
Telomere Dysfunction–Related Serological Markers Are Associated With Type 2 Diabetes
Xiao, F., Zheng, X., Cui, M., Shi, G., Chen, X., Li, R., Song, Z., Rudolph, K. L., Chen, B., & Ju, Z. (2011) · Diabetes Care · doi:10.2337/dc10-2431 · Cited by 36
“Recent experimental evidence suggested that telomere attrition provokes senescenceassociated secretion of inflammatory cytokines (22).”
BackgroundA New Strategy for Treatment of Liver Fibrosis: Letting MicroRNAs Do the Job
Chen, S., Zheng, M., Shi, K., Yang, T., & Chen, Y. (2012) · BioDrugs · doi:10.1007/s40259-012-0005-2 · Cited by 35
Radiation-Induced Bystander Response: Mechanism and Clinical Implications
Suzuki, K., & Yamashita, S. (2013) · Advances in Wound Care · doi:10.1089/wound.2013.0468 · Cited by 39
Friends and foes: Extracellular vesicles in aging and rejuvenation
Lananna, B. V., & Imai, S. (2021) · FASEB BioAdvances · doi:10.1096/fba.2021-00077 · Cited by 35
Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?
van Schaik, T., Chen, K., & Shah, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.678562 · Cited by 38
“Furthermore, the amount of SASP cells and consequently levels of SASPassociated cytokines is associated with genetic deficiencies in regular senescent pathways such as p53 and PTEN (93, 94).”
BackgroundTranscriptomic Analysis of Cellular Senescence: One Step Closer to Senescence Atlas
Kim, S., & Kim, C. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.2239 · Cited by 33
“cells affect the surrounding cells by secreting senescence-associated secretory phenotypes (SASPs), including cytokines, chemokines, growth factors, and matrix metalloproteases (Acosta et al., 2008; Coppé et al., 2008; Krtolica et al., 2001).”
BackgroundInfluentialTodhunter, M. E., Sayaman, R. W., Miyano, M., & LaBarge, M. A. (2018) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2018.05.016 · Cited by 33
“Senescent cells secrete molecules that cause chronic inflammatory states, which are a characteristic of aging (the so-called SASP) [46].”
BackgroundMacià, A., Vaquero, M., Gou-Fàbregas, M., Castelblanco, E., Valdivielso, J. M., Anerillas, C., Mauricio, D., Matías‐Guiu, X., Ribera, J., & Encinas, M. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.161 · Cited by 37
Kennedy, L. L., Hargrove, L. A., Demieville, J., Bailey, J. M., Dar, W. A., Polireddy, K., Chen, Q., Rubin, M. I. N., Sybenga, A. B., DeMorrow, S., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.11.016 · Cited by 35
Senescent cells and SASP in cancer microenvironment: New approaches in cancer therapy
Özdemir, A., Demir, Y. D. Ş., Yeşilyurt, Z. E., & Ark, M. (2022) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2022.10.002 · Cited by 36
Antibiotics that target mitochondria extend lifespan in C. elegans
Bonuccelli, G., Brooks, D. R., Shepherd, S., Sotgia, F., & Lisanti, M. P. (2023) · Aging · doi:10.18632/aging.205229 · Cited by 37
The Role of STAT1 for Crosstalk between Fibroblasts and Colon Cancer Cells
Kaler, P., Owusu, B. Y., Augenlicht, L. H., & Klampfer, L. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00088 · Cited by 34
MAVS Antagonizes Human Stem Cell Senescence as a Mitochondrial Stabilizer
Wang, C., Yang, K., Liu, X., Wang, S., Song, M., Belmonte, J. C. I., Qu, J. T., Liu, G., & Zhang, W. (2023) · Research · doi:10.34133/research.0192 · Cited by 37
Naipauer, J., Rosario, S., Gupta, S., Premer, C., Méndez-Solís, O., Schlesinger, M., Ponzinibbio, V., Jain, V., Gay, L. A., Renne, R., et al. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1008221 · Cited by 32
“In order to fulfill all the hallmarks for establishing cell senescence [60, 61] we measured 1) Markers for Inhibition of the cell cycle and levels of cell cycle arrest proteins 2) Expression of acidic beta-galactosidase and 3) Upregulation of Senescence Associated Secretory Phenotype (SASP) and other senescence marker…”
MethodAge-associated alterations in inducible gene transcription in human CD4+ T lymphocytes
Bektas, A., Zhang, Y., Wood, W. H., Becker, K. G., Madara, K., Ferrucci, L., & Sen, R. (2013) · Aging · doi:10.18632/aging.100522 · Cited by 31
“Along with IL-6, CXCLl is one of the cytokines associated with senescence-associated secretory program (SASP) [35, 36].”
BackgroundRemoving all obstacles: A critical role for p53 in promoting tissue renewal
Schoppy, D. W., Ruzankina, Y., & Brown, E. J. (2010) · Cell Cycle · doi:10.4161/cc.9.7.11194 · Cited by 32
Guaraldi, G., Milić, J., Cesari, M., Leibovici, L., Mandreoli, F., Missier, P., Rozzini, R., Cattelan, A. M., Motta, F., Mussini, C., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101686 · Cited by 34
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.